ProSomnus SPAC Presentation Deck

Front Line OSA Therapy (FLOSAT Study) Medical Affairs: Active Studies ProSomnus continues to invest in clinical support and professional education, far exceeding previous clinical data for legacy OAT Study Severe OSA Indication (SOS Study) Harvard Brigham's Hypoxic Burden Study Objective Compare the efficacy of ProSomnus with CPAP as frontline therapy Secure FDA severe OSA indication for use by demonstrating safety and effectiveness Does ProSomnus reduce hypoxic burden for patients with OSA, which is predictive of cardiovascular events? Design Prospective, controlled, cross over trial Prospective, controlled, single arm, multi-center, trial Prospective, controlled, single arm trial Other Studies: Dose study, Mt. Sinai Hospital ▪ 5 scientific abstracts accepted for publication at World Sleep Congress ▪ 5 scientific abstracts accepted for publication at AADSM Meeting ■ 4 scientific abstracts accepted for publication at AASM Meeting Status 40/121 patients enrolled FDA-approved study design Q1 '22 O 28/28 enrolled; 8/28 at 1-year follow up PROSOMNUS SLEEP TECHNOLOGIES Expected Next Steps Preliminary data available in Q4 '22 Enroll patients by end of Q2 '22 Preliminary results show clinically significant improvements in hypoxic burden 20 STRICTLY CONFIDENTIAL

View entire presentation